Oncolytic viruses (OV) represent a relatively new therapeutic paradigm that employs the ability of viruses to infect tumor cells, multiply in them, destroy them and spread to other tumor cells in successive rounds. Over the last decade, a first wave of oncolytic viruses has been tested in the clinical realm, including OVs based on herpes simplex virus Type 1 (HSV-1). These clinical trials have not shown evidence of dose-limiting toxicities in humans when injected directly into malignant gliomas or into brain surrounding the glioma, but evidence for efficacy in these small scale trials has also been lacking, probably due to their high degree of attenuation. We have now developed and published preclinical efficacy results on a new, more potent oncolytic virus (rQNestin34.5) that employs the human nestin promoter-enhancer element to drive expression of the HSV1 gene, Yi34.5, encoding the viral protein ICP34.5. This strategy allows the virus to replicate to high yields in cells that express nestin, while replication in cells that do not express nestin is severely attenuated. We and others have shown that nestin is expressed in a large proportion of gliomas, while it is not expressed in normal adult brain. In fact, nestin is one of the markers reported to distinguish the glioma "stem-like" or "initiator" subpopulation thought to provide the self-renewal capabilities of these tumors. In addition, we have published that immunomodulation with cyclophosphamide further enhances the potency and antiglioma efficacy of rQNestin34.5. Therefore, at this juncture, our published efficacy studies, revealing impressive and significant antiglioma properties of this OV, encourage us to pursue preclinical toxicity studies in mice models of HSV1 toxicity (and non-human primate models) using preclinical lots of OV. We thus propose the following four specific aim/milestones to justify two future clinical trials in humans: Milestone/Aim 1: Bioequivalency of rQNestin34.5v.2 and of reagents and standard operating protocol for future clinical grade production;Milestone/Aim 2: Validation of therapeutic efficacy and safety monitoring with rQNestin34.5v.2;Milestone/Aim 3: Validation of safety monitoring with rQNestin34.5v.2 in presence of CPA: Milestone/Aim 4: Final toxicology/biodistribution study with GMP-grade clinical lot . The successful pursuit of milestone 4 will permit us to approach regulatory agencies to start a phase I trial in patients with recurrent malignant glioma using rQNestin34.5v.2 + CPA immunomodulation and subsequently a phase I trial in newly diagnosed glioma using rQNestin34.5v.2 + CPA immunomodulation + standard therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project--Cooperative Agreements (U01)
Project #
7U01NS061811-05
Application #
8338450
Study Section
National Institute of Neurological Disorders and Stroke Initial Review Group (NSD)
Program Officer
Mcgavern, Linda
Project Start
2008-09-30
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2014-08-31
Support Year
5
Fiscal Year
2012
Total Cost
$1,378,673
Indirect Cost
$594,290
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Kaufmann, Johanna K; Chiocca, E Antonio (2014) Glioma virus therapies between bench and bedside. Neuro Oncol 16:334-51
Chiocca, E Antonio; Rabkin, Samuel D (2014) Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2:295-300
Okemoto, Kazuo; Kasai, Kazue; Wagner, Benjamin et al. (2013) DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas. Clin Cancer Res 19:5952-9
Alvarez-Breckenridge, Christopher A; Yu, Jianhua; Price, Richard et al. (2012) The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon. J Virol 86:4566-77
Nakashima, Hiroshi; Kaur, Balveen; Chiocca, E A (2010) Directing systemic oncolytic viral delivery to tumors via carrier cells. Cytokine Growth Factor Rev 21:119-26
Kaur, Balveen; Cripe, Timothy P; Chiocca, E Antonio (2009) "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 9:341-55
Alvarez-Breckenridge, Christopher; Kaur, Balveen; Chiocca, E Antonio (2009) Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev 109:3125-40